Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant dimeglumine injection vs aprepitant capsules for prevention of chemotherapy-induced nausea and vomiting
CTR20200963Phase 3Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Yichang Humanwell Pharmaceutical Co., Ltd. Primary endpoint: Complete response rate over overall phase. Started May 2020; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20200963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200963.